Healthcare provider profile · identity verified

Anthony M Griffin, MD

Allopathic & Osteopathic Physicians|Internal Medicine · JACKSONVILLE, IL · NPI 1770558603

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Anthony M Griffin, MD received $14.10 in general payments during 2025 across 1 reported records.

ABBVIE INC. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

A separate comparison found the same explicitly named product in public Medicare Part D data: Synthroid.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 48 claims for Synthroid by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$14.10

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ABBVIE INC.	Unresolved — no canonical attribution shown	$14.10	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$14.10	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
SYNTHROID Normalized: synthroid	Drug	ABBVIE INC.	$14.10	1	2025
Source payment records 2025-05-06 · ABBVIE INC. · $14.10 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
SYNTHROID synthroid	2025	Synthroid	2024	48	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	LINZESS open payments reported associated product	CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608	Linzess · 2024 Exact normalized brand match · 1 Part D row	22	suppressed by CMS
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	SYNTHROID open payments reported associated product	CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636	Synthroid · 2024 Exact normalized brand match · 1 Part D row	48	11

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	1721	435
Lisinopril	Lisinopril	1343	317
Omeprazole	Omeprazole	957	227
Levothyroxine Sodium	Levothyroxine Sodium	921	220
Amlodipine Besylate	Amlodipine Besylate	891	223
Metformin Hcl	Metformin Hcl	696	174
Metoprolol Succinate	Metoprolol Succinate	656	165
Citalopram Hbr	Citalopram Hydrobromide	585	143
Hydrochlorothiazide	Hydrochlorothiazide	566	140
Losartan Potassium	Losartan Potassium	566	153
Simvastatin	Simvastatin	541	132
Pantoprazole Sodium	Pantoprazole Sodium	539	127
Potassium Chloride	Potassium Chloride	512	116
Gabapentin	Gabapentin	500	117
Warfarin Sodium	Warfarin Sodium	484	61
Furosemide	Furosemide	458	102
Metoprolol Tartrate	Metoprolol Tartrate	450	102
Glipizide	Glipizide	440	112
Famotidine	Famotidine	425	104
Albuterol Sulfate Hfa	Albuterol Sulfate	397	100
Tamsulosin Hcl	Tamsulosin Hcl	366	89
Eliquis	Apixaban	336	62
Alendronate Sodium	Alendronate Sodium	324	80
Pravastatin Sodium	Pravastatin Sodium	304	71
Rosuvastatin Calcium	Rosuvastatin Calcium	304	82
Meloxicam	Meloxicam	289	70
Tramadol Hcl	Tramadol Hcl	261	55
Diclofenac Sodium	Diclofenac Sodium	220	52
Allopurinol	Allopurinol	210	54
Fluoxetine Hcl	Fluoxetine Hcl	208	43
Zolpidem Tartrate	Zolpidem Tartrate	201	40
Pioglitazone Hcl	Pioglitazone Hcl	200	61
Montelukast Sodium	Montelukast Sodium	199	44
Sertraline Hcl	Sertraline Hcl	196	39
Carvedilol	Carvedilol	189	45
Doxazosin Mesylate	Doxazosin Mesylate	182	38
Atenolol	Atenolol	181	44
Clopidogrel	Clopidogrel Bisulfate	180	40
Naproxen	Naproxen	179	38
Fluticasone Propionate	Fluticasone Propionate	174	64
Lovastatin	Lovastatin	173	37
Alprazolam	Alprazolam	165	40
Duloxetine Hcl	Duloxetine Hcl	149	35
Finasteride	Finasteride	131	23
Trazodone Hcl	Trazodone Hcl	131	33
Oxybutynin Chloride	Oxybutynin Chloride	126	19
Bupropion Hcl Sr	Bupropion Hcl	123	26
Fenofibrate	Fenofibrate	116	25
Oxybutynin Chloride Er	Oxybutynin Chloride	112	26
Hydroxyzine Hcl	Hydroxyzine Hcl	111	25
Venlafaxine Hcl Er	Venlafaxine Hcl	111	22
Hydralazine Hcl	Hydralazine Hcl	105	26
Paroxetine Hcl	Paroxetine Hcl	105	19
Ozempic	Semaglutide	103	18
Amitriptyline Hcl	Amitriptyline Hcl	100	19
Baclofen	Baclofen	99	16
Ezetimibe	Ezetimibe	96	23
Escitalopram Oxalate	Escitalopram Oxalate	93	23
Enalapril Maleate	Enalapril Maleate	92	24
Metformin Hcl Er	Metformin Hcl	91	23
Buspirone Hcl	Buspirone Hcl	86	19
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	85	17
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	79	18
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	79	22
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	77	13
Propranolol Hcl	Propranolol Hcl	76	14
Ropinirole Hcl	Ropinirole Hcl	74	16
Glipizide Er	Glipizide	67	18
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	65	18
Celecoxib	Celecoxib	64	20
Xarelto	Rivaroxaban	63	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	61	16
Triamcinolone Acetonide	Triamcinolone Acetonide	61	34
Meclizine Hcl	Meclizine Hcl	60	15
Glimepiride	Glimepiride	59	14
Januvia	Sitagliptin Phosphate	58	13
Donepezil Hcl	Donepezil Hcl	56	15
Clonazepam	Clonazepam	55	14
Nystatin	Nystatin	54	14
Quetiapine Fumarate	Quetiapine Fumarate	53	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	52	16
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	52	18
Tizanidine Hcl	Tizanidine Hcl	52	suppressed
Lorazepam	Lorazepam	51	13
Synthroid	Levothyroxine Sodium	48	11
Valsartan	Valsartan	48	12
Valacyclovir	Valacyclovir Hcl	47	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	46	suppressed
Lactulose	Lactulose	46	suppressed
Etodolac	Etodolac	45	suppressed
Spironolactone	Spironolactone	44	14
Topiramate	Topiramate	44	suppressed
Trulicity	Dulaglutide	43	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	42	17
Lamotrigine	Lamotrigine	42	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	42	suppressed
Memantine Hcl	Memantine Hcl	40	suppressed
Divalproex Sodium Er	Divalproex Sodium	36	suppressed
Ondansetron Hcl	Ondansetron Hcl	36	14
Ventolin Hfa	Albuterol Sulfate	36	17
Esomeprazole Magnesium	Esomeprazole Magnesium	35	suppressed
Testosterone Cypionate	Testosterone Cypionate	35	suppressed
Carbamazepine	Carbamazepine	33	suppressed
Nifedipine Er	Nifedipine	33	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	33	suppressed
Arnuity Ellipta	Fluticasone Furoate	32	suppressed
Jardiance	Empagliflozin	32	suppressed
Mirtazapine	Mirtazapine	31	suppressed
Ondansetron Odt	Ondansetron	31	14
Benazepril Hcl	Benazepril Hcl	30	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	30	26
Felodipine Er	Felodipine	30	suppressed
Temazepam	Temazepam	30	suppressed
Bupropion Xl	Bupropion Hcl	29	suppressed
Lantus	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	29	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	28	suppressed
Risperidone	Risperidone	28	suppressed
Azelastine Hcl	Azelastine Hcl	27	suppressed
Carbidopa-Levodopa	Carbidopa/Levodopa	27	suppressed
Digoxin	Digoxin	27	suppressed
Klor-Con M20	Potassium Chloride	27	suppressed
Prednisone	Prednisone	27	11
Tiagabine Hcl	Tiagabine Hcl	27	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	26	suppressed
Irbesartan	Irbesartan	26	suppressed
Propranolol Hcl Er	Propranolol Hcl	26	suppressed
Sucralfate	Sucralfate	26	suppressed
Torsemide	Torsemide	26	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	25	suppressed
Diazepam	Diazepam	24	suppressed
Rizatriptan	Rizatriptan Benzoate	24	suppressed
Nabumetone	Nabumetone	23	suppressed
Divalproex Sodium	Divalproex Sodium	22	suppressed
Ibuprofen	Ibuprofen	22	suppressed
Linzess	Linaclotide	22	suppressed
Nystop	Nystatin	22	11
Pregabalin	Pregabalin	22	suppressed
Wixela Inhub	Fluticasone Propion/Salmeterol	22	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	21	suppressed
Verapamil Sr	Verapamil Hcl	21	suppressed
Wegovy	Semaglutide	21	suppressed
Levetiracetam	Levetiracetam	20	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	20	19
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	20	suppressed
Glyburide	Glyburide	19	suppressed
Lansoprazole	Lansoprazole	19	suppressed
Myrbetriq	Mirabegron	19	suppressed
Acyclovir	Acyclovir	18	suppressed
Fosinopril Sodium	Fosinopril Sodium	18	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	18	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	17	17
Methocarbamol	Methocarbamol	17	suppressed
Novolog Flexpen	Insulin Aspart	17	suppressed
Phenobarbital	Phenobarbital	17	suppressed
Terazosin Hcl	Terazosin Hcl	17	suppressed
Amiodarone Hcl	Amiodarone Hcl	16	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	16	suppressed
Hydrocortisone	Hydrocortisone	16	13
Phenytoin Sodium Extended	Phenytoin Sodium Extended	16	suppressed
Ramipril	Ramipril	16	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	15	suppressed
Chlorthalidone	Chlorthalidone	15	suppressed
Budesonide	Budesonide	14	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	14	suppressed
Labetalol Hcl	Labetalol Hcl	14	suppressed
Methylprednisolone	Methylprednisolone	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	14	14
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	14	suppressed
Benazepril-Hydrochlorothiazide	Benazepril/Hydrochlorothiazide	13	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Dapsone	Dapsone	13	suppressed
Doxepin Hcl	Doxepin Hcl	13	suppressed
Estradiol	Estradiol	13	suppressed
Indapamide	Indapamide	13	suppressed
Latanoprost	Latanoprost	13	suppressed
Prazosin Hcl	Prazosin Hcl	13	suppressed
Tolterodine Tartrate Er	Tolterodine Tartrate	13	suppressed
Venlafaxine Hcl	Venlafaxine Hcl	13	suppressed
Carbamazepine Er	Carbamazepine	12	suppressed
Fenofibrate	Fenofibrate,micronized	12	suppressed
Nebivolol Hcl	Nebivolol Hcl	12	suppressed
Nitroglycerin Patch	Nitroglycerin	12	suppressed
Orencia	Abatacept	12	suppressed
Oxcarbazepine	Oxcarbazepine	12	suppressed
Pilocarpine Hcl	Pilocarpine Hcl	12	suppressed
Rabeprazole Sodium	Rabeprazole Sodium	12	suppressed
Valproic Acid	Valproic Acid	12	suppressed
Aripiprazole	Aripiprazole	11	suppressed
Diphenoxylate-Atropine	Diphenoxylate Hcl/Atropine	11	suppressed
Insulin Syringe	Syringe And Needle,insulin,1ml	11	suppressed
Terbinafine Hcl	Terbinafine Hcl	11	suppressed
Tradjenta	Linagliptin	11	suppressed
Verapamil Er	Verapamil Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$14.10 · 1 records	ABBVIE INC.	SYNTHROID	2	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Synthroid play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error